<DOC>
	<DOCNO>NCT00641303</DOCNO>
	<brief_summary>RATIONALE : Acupuncture may help relieve muscle bone pain cause aromatase inhibitor therapy , letrozole , exemestane , anastrozole . PURPOSE : This randomized phase II trial study acupuncture see well work reduce muscle bone symptom woman receive letrozole , exemestane , anastrozole stage 0 , stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Acupuncture Reducing Muscle Bone Symptoms Women Receiving Letrozole , Exemestane , Anastrozole Stage 0 , Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine acupuncture reduce aromatase inhibitor ( AI ) -associated musculoskeletal symptom severity , term function pain , woman stage 0-III breast cancer . Secondary - To assess acupuncture decrease oral analgesic use patient . - To assess acupuncture decrease proportion patient change discontinue AI therapy . - To assess acupuncture improve menopausal symptom , mood ( i.e. , depression anxiety ) , sleep quality sleep disturbance , overall quality life patient . - To assess acupuncture change plasma concentration estrogen ( i.e. , E1 , E2 , E1S ) , cytokine profile , beta endorphin . OUTLINE : This multicenter study . Patients stratify accord participation aromatase inhibitor trial , `` A Multicenter Randomized Clinical Trial Correlating Effects 24 Months Exemestane Letrozole Surrogate Markers Response With Aromatase Polymorphism '' ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I ( control ) : Patients receive 8 weekly session sham acupuncture treatment comprise 20 minute non-penetrating device consist retractable needle adhesive tube skin use Park Sham Device ( PSD ) 14 non-acupuncture point . Patients may receive 4 free acupuncture session ( sham ) 12-week ( previously 24-week ) follow-up visit . - Arm II ( treatment ) : Patients receive 8 weekly session acupuncture treatment comprise 20 minute needle insertion 15 acupuncture point include CV 4 , CV 6 , CV12 bilateral LI 4 , MH 6 , GB 34 , ST 36 , KI 3 , BL 65 . Quality life assess periodically measure change symptom may relate hot flash estrogen deprivation ( i.e. , menopausal symptom , mood [ depression anxiety ] , sleep quality , overall quality life use menopausal symptom checklist ) ; Hot Flash Related Daily Interference Scale ( HFRDI ) Hot Flash Daily Diary ; Pittsburgh Sleep Quality Index ( PSQI ) ; Center Epidemiologic Studies Depression Scale ( CESD ) ; Hospital Anxiety Depression Scale ( HADS-A ) ; EuroQOL . Patients complete questionnaire include Health Assessment Questionnaire ( HAQ ) visual analog scale ( VAS ) ass pain global health status baseline , 4 8 week acupuncture sham acupuncture , follow-up 12 week ( previously 24 week ) . The average amount daily oral analgesic usage assess week 0 , 4 , 8 , 12 ( previously 24 ) . Patients undergo blood sample collection periodically correlative study . Samples analyze plasma concentration estrogen ( i.e. , estrone E1 , estradiol E2 , estrone sulfate E1S ) via HPLC-MS/MS , level 35 serum cytokine via addressable laser bead immunoassay ( ALBIA ) classical sandwich ELISA , cytokines soluble receptor via classical sandwich ELISA technique , Beta-endorphin via competitive ELISA . All patient follow 12 week ( previously 24 week ) . Patients arm I may follow additional 4 week choose receive free acupuncture session .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive carcinoma breast Stage 0III disease Estrogen receptor and/or progesterone receptorpositive immunohistochemical staining Must receive standard dose aromatase inhibitor ( AI ) therapy ( i.e. , letrozole 2.5 mg daily , exemestane 25 mg daily , anastrozole 1 mg daily ) AI therapy ongoing ≥ 1 month treatment expect continue AIassociated musculoskeletal symptom , define ≥ 1 following : Physicianconfirmed AIassociated musculoskeletal symptom Patients concurrently enrol clinical trial , `` A MultiCenter Randomized Clinical Trial Correlating Effects 24 Months Exemestane Letrozole Surrogate Markers Response Aromatase Polymorphism , '' meet referral criterion rheumatological evaluation No know metastatic ( stage IV ) breast cancer PATIENT CHARACTERISTICS : ECOG performance status 02 Female Menopausal status specify PRIOR CONCURRENT THERAPY : No prior acupuncture within past 12 month . No concurrent systemic therapy ( i.e. , chemotherapy , biologic therapy , radiotherapy ) unless approval give Protocol Chair</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>pain</keyword>
	<keyword>fatigue</keyword>
	<keyword>hot flash</keyword>
	<keyword>sleep disorder</keyword>
	<keyword>depression</keyword>
	<keyword>anxiety disorder</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>